Adult-type soft tissue sarcomas in pediatric-age patients: experience at the Istituto Nazionale Tumori in Milan.

PURPOSE Nonrhabdomyosarcoma soft tissue sarcomas are a heterogeneous group of tumors for which optimal treatment remains controversial. We report on a large group of 182 patients younger than 18 years old treated at a single institution over a 25-year period. PATIENTS AND METHODS In this relatively homogeneous subgroup of adult-type histotypes, surgery was the mainstay of treatment; radiotherapy was administered to 73 patients, and chemotherapy was administered to 114 patients (70 received chemotherapy as adjuvant therapy). RESULTS Overall survival at 5 years was 89% in patients who underwent complete resection at diagnosis, 79% in patients who had marginal resection, 52% in initially unresected patients, and 17% in patients with metastases at onset. Outcome was unsatisfactory in patients with large and high-grade tumors, even after gross resection; adjuvant chemotherapy seemed to improve the results in this group. Initially unresected patients who responded well to chemotherapy and subsequently underwent complete resection had an event-free survival rate of approximately 70%. The rate of response to chemotherapy was 58%. CONCLUSION The identification of prognostic variables should enable risk-adapted therapies to be planned. Patients with initially unresectable disease and patients with resected large and high-grade tumors are at high risk of metastases and treatment failure. Although the limits of this retrospective analysis are self-evident, our data would suggest that intensive chemotherapy (with an ifosfamide-doxorubicin regimen) might have a more significant role in these patients than what is generally assumed.

[1]  R. Benjamin,et al.  High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M Bonetti,et al.  Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C. Arndt,et al.  Nonrhabdomyosarcoma Soft Tissue Sarcomas in Children: The Mayo Clinic Experience , 2000, Clinical orthopaedics and related research.

[4]  B. Rao,et al.  Nonrhabdomyosarcoma in children: prognostic factors influencing survival. , 1993, Seminars in surgical oncology.

[5]  D. Cox Regression Models and Life-Tables , 1972 .

[6]  R. DeMatteo The GIST of targeted cancer therapy: A tumor (Gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571) , 2002, Annals of Surgical Oncology.

[7]  S. Spunt,et al.  Soft tissue sarcomas of childhood. , 2004, Cancer treatment reviews.

[8]  A. Santoro,et al.  Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  C. Antonescu,et al.  Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Crowley,et al.  An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Jonathan J. Lewis,et al.  Histopathologic Type: An Independent Prognostic Factor in Primary Soft Tissue Sarcoma of the Extremity? , 2003, Annals of Surgical Oncology.

[12]  J. Edmonson,et al.  Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  W. J. Conover,et al.  Practical Nonparametric Statistics , 1972 .

[14]  A. Pappo,et al.  Role of adjuvant chemotherapy in the treatment of surgically resected pediatric nonrhabdomyosarcomatous soft tissue sarcomas: A Pediatric Oncology Group Study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  D. Crowther Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data , 1997, The Lancet.

[16]  A. Pappo,et al.  Nonrhabdomyosarcoma soft tissue sarcomas in children: is age at diagnosis an important variable? , 2000, Journal of pediatric surgery.

[17]  W. Enneking,et al.  A System for the Surgical Staging of Musculoskeletal Sarcoma , 1980, Clinical orthopaedics and related research.

[18]  J. Coindre,et al.  Soft‐tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system , 1984, International journal of cancer.

[19]  S. Steinberg,et al.  Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Carli,et al.  Summary of the International Symposium on Childhood Non-Rhabdomyosarcoma Soft-Tissue Sarcomas, Padua, Italy, February 10-12, 1994. , 1996, Medical and pediatric oncology.

[21]  T. Merchant,et al.  Clinical features and outcome of initially unresected nonmetastatic pediatric nonrhabdomyosarcoma soft tissue sarcoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  T. Merchant,et al.  Prognostic factors for children and adolescents with surgically resected nonrhabdomyosarcoma soft tissue sarcoma: an analysis of 121 patients treated at St Jude Children's Research Hospital. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  A. Pappo,et al.  A pilot study of vincristine, ifosfamide, and doxorubicin in the treatment of pediatric non-rhabdomyosarcoma soft tissue sarcomas. , 1998, Medical and pediatric oncology.

[24]  D. Green,et al.  Treatment of unresectable or metastatic pediatric soft tissue sarcomas with surgery, irradiation, and chemotherapy: a Pediatric Oncology Group study. , 1998, Medical and pediatric oncology.

[25]  F. Collin,et al.  Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  D H Leung,et al.  Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  V. Bramwell Adjuvant chemotherapy for adult soft tissue sarcoma: Is there a standard of care? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Munsell,et al.  Synovial sarcoma of childhood and adolescence: a multicenter, multivariate analysis of outcome. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  E. Gehan,et al.  The intergroup rhabdomyosarcoma study‐I. A final report , 1988, Cancer.

[30]  G. Rosen,et al.  Synovial sarcoma. Uniform response of metastases to high dose ifosfamide , 1994, Cancer.

[31]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .